glp 1 analogues ppt Exploring the Science and Practice of GLP-1 Receptor Agonists: An Update on Current and Emerging Evidence Mechanisms of Action and Therapeutic

SURPASS-CVOT is a large-scale, randomized, double-blind, multinational phase III clinical trial that enrolled 13,299 Type 2 Diabetes Mellitus patients with increased cardiovascular risk

There is no definitive evidence supporting probiotics, digestive enzymes, or most other supplements specifically for GLP-1 nausea, though individual patients may report subjective benefit

To mitigate the well-established risk of DKA, patients were required to have a total daily insulin requirement of 0.5 U/kg, undergo frequent home ketone monitoring and receive structured education [28]

Each challengewhether its new patient types, higher expectations, or expanded service demandis fixable with the right training and support .

J.ScheidA.et al (2002)

Perez-Moreiras, J